Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Virtual reality could sharpen MS brain testing

NCT ID NCT01805336

Knowledge-focused Sponsor: University Hospital, Caen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared traditional pencil-and-paper tests with virtual reality tasks (like driving simulations and a virtual supermarket) to assess attention and executive function in 60 people with relapsing-remitting multiple sclerosis. The goal was to see if VR can better detect real-world cognitive problems. Researchers hope VR may lead to more accurate assessments and better cognitive rehabilitation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more accurate, real-world assessments of cognitive problems in MS patients.
What could go wrong
This is a small, completed study comparing test methods, not a treatment trial. The virtual reality tests may not prove more useful than standard tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2013

Finished

Jul 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients only : * Diagnosis of RR-MS in accordance with the Polman et al. criteria (2011) * Expanded Disability Status Scale (EDSS) \< 6 * Any disease duration * Patients and healthy subjects : * Men and women * Ages 30-60 years inclusive * Score of \> 130 on the Mattis Dementia Rating Scale (DRS) * Score of \< 15 on the Montgomery and Asberg Depression Rating Scale (MADRS) * French native language * Licensed drivers (\> 2 years) * Experienced drivers (\> 5000 km / year) * Normal or corrected visual acuity greater than or equal to 6/10 * Sign informed consent Exclusion Criteria: * Patients only : * Any relapse or corticosteroids therapy within 30 days * Under guardianship * Patients and healthy subjects * Other neurological, psychiatric or developmental disease * Serious systemic disease * Sequelae of brain injury * Antidepressants or anxiolytics treatment within 4 weeks * Treatment known to interfere with cognition (e.g. psychostimulant) within 3 months * Alcohol \> 28 units / week * Addiction * Cognitive assessment within a year (including all or part of the assessment proposed in this study) * Sensory or motor failure incompatible with study tasks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsing-remitting multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsing-remitting multiple sclerosis

Contacts and locations

Locations

  • Department of Neurologie, Caen Hospital University

    Caen, Basse-Normandie, 14033, France

  • Inserm Unit 1075 Comete, Caen Hospital University

    Caen, Basse-Normandie, 14033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.